CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
CHAMPIONS ONCOLOGY, INC.
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026
$4.69−0.01 (-0.21%)
Close on Oct 19, 2026
- Market cap
- $65.18M
- P/E (TTM)
- –
- Dividend yield
- –
CHAMPIONS ONCOLOGY, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacology services | $58.06M | $57.13M | $55.28M | $50.76M | $48.75M | $48.59M | $50.35M | $49.87M | $48.25M | $47.04M | $46.27M | $47.21M | 95.7% | +19.1% |
| TOS data license revenue | $1.35M | $764.00K | $644.00K | $5.14M | $4.99M | $4.68M | – | – | – | – | – | – | 2.2% | -73.0% |
| Other TOS revenue | $1.26M | $1.53M | $2.02M | $2.52M | $3.15M | $3.68M | $3.74M | $3.70M | $3.41M | $3.10M | $2.93M | $2.75M | 2.1% | -60.1% |
| Personalized oncology services | – | – | – | – | – | $0 | $0 | $0 | $0 | $18.00K | $17.00K | $23.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Champions Oncology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.